Study of febuxostat and inosine for Parkinson's disease
Treatments studied
Part of Brain & nervous system clinical trials.
This trial tests whether a combination of two supplements, febuxostat and inosine, can help people with Parkinson's disease. It aims to see if this treatment is safe and may improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with Parkinson's disease by a specialist.
- Your Parkinson's disease is mild to moderate (able to walk and stand, with some movement issues).
- You have been on the same Parkinson's medications for at least 3 months without changes.
- You are not taking certain medications like azathioprine, allopurinol, or any supplement containing inosine.
- You do not have serious kidney or liver problems, and no history of surgery for Parkinson's.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental medicine called ENERGI-F705 to see if it can help people with Parkinson's disease. It focuses on people who have had the disease for at least 2 years and are currently on standard Parkinson's medications, without major movement complications.
This trial tests a new drug called VT-5006 to see if it is safe for people with Parkinson's disease. It focuses on those who have stomach or bowel issues, like constipation.
This study tests an experimental drug, MTX325, in people with Parkinson's disease. The goal is to see if it is safe and how the body processes it, which may lead to new treatment options.
This trial checks how a new drug interacts with two other medicines (amiodarone and febuxostat) in healthy volunteers. It helps doctors understand safe dosing before testing in patients.
This trial tests a new oral medicine, GT-02287, to see if it can help people with early Parkinson's disease. It aims to improve symptoms and slow the disease, and it also tracks how the medicine affects certain markers in the body.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
Hear when a new Parkinson's Disease (PD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.